이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer

2026년 5월 27일 업데이트: First Affiliated Hospital of Zhejiang University

Efficacy and Safety of a PCSK9 Inhibitor (Tafolecimab) Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer: A Multicenter, Prospective, Single-Arm Exploratory Study

Background:

Gastric cancer remains a significant health burden globally, particularly in China, where the majority of patients present with advanced disease at diagnosis. While immune checkpoint inhibitors (ICIs) targeting PD-1 have revolutionized treatment for various malignancies, their efficacy in proficient mismatch repair (pMMR) or microsatellite stable (MSS) gastric cancer-which constitutes over 85% of cases-remains limited. Recent Phase III trials (CheckMate 649, ATTRACTION-04, Orient-16) have demonstrated that combining PD-1 inhibitors with chemotherapy improves outcomes in advanced gastric cancer, leading to approved indications. However, the benefit in pMMR/MSS populations is modest, highlighting an urgent need for novel combination strategies to overcome immunotherapy resistance.

Preclinical research published in Nature (Liu et al., 2020) revealed that inhibiting PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9)-a key regulator of cholesterol metabolism-can potentiate immune checkpoint therapy through a novel mechanism independent of its lipid-lowering function. PCSK9 inhibition was shown to increase tumor cell surface expression of MHC class I molecules by preventing their lysosomal degradation, thereby enhancing tumor antigen presentation and promoting cytotoxic T lymphocyte infiltration. This mechanistic insight suggests that combining a PCSK9 inhibitor with PD-1 blockade could synergistically improve antitumor immunity, particularly in immunologically "cold" tumors like pMMR/MSS gastric cancer.

Tafolecimab is the first domestically developed fully humanized PCSK9 monoclonal antibody approved in China for hypercholesterolemia, with a favorable safety profile and extended half-life. Based on this strong preclinical rationale and the established efficacy of PD-1 plus chemotherapy in gastric cancer, this investigator-initiated trial aims to clinically translate the concept of PCSK9 inhibition as an immunomodulatory strategy.

Study Population:

This study will enroll 30 patients with the following key eligibility criteria:

Inclusion: Adults aged 18-75 years with histologically confirmed pMMR/MSS gastric or gastroesophageal junction adenocarcinoma; initially unresectable or advanced disease (including metastatic); ECOG performance status 0-1; measurable disease per RECIST v1.1; adequate organ function.

Exclusion: HER2-positive, EBER-positive, or CLDN18.2-positive tumors; prior systemic anticancer therapy for advanced disease; active autoimmune disease requiring immunosuppression; uncontrolled intercurrent illness; LDL-C <30 mg/dL; history of PCSK9 inhibitor allergy; prior exposure to anti-PD-1/PD-L1 or PCSK9-targeted therapies.

Study Objectives:

This is a multicenter, prospective, single-arm exploratory trial with a safety run-in phase (first 6 patients monitored for dose-limiting toxicities). The treatment regimen consists of:

Sintilimab (PD-1 inhibitor): 200 mg IV, day 1, every 3 weeks (Q3W) Tafolecimab (PCSK9 inhibitor): 300 mg subcutaneous injection, day 1, Q3W (dose reduction to 150 mg if DLTs occur) SOX chemotherapy: Oxaliplatin 130 mg/m² IV, day 1 + S-1 40 mg/m² orally twice daily, days 1-14, Q3W cycles Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.

Primary Endpoint:

Objective Response Rate (ORR) assessed by RECIST v1.1

Secondary Endpoints:

Progression-Free Survival (PFS) Disease Control Rate (DCR) Conversion surgery rate and R0 resection rate Pathological Complete Response (pCR) and Major Pathological Response (MPR) rates in resected patients Overall Survival (OS) Safety and tolerability (incidence of TRAEs, ≥Grade 3 AEs, irAEs per CTCAE v5.0)

Exploratory Endpoints:

Association between tumor biomarkers (including PD-L1 CPS, H. pylori infection status, and tumor PCSK9 expression) and treatment efficacy Multi-omics analyses using paired pre- and post-treatment tumor tissue, peripheral blood, and fecal samples

Sample Size and Duration:

A fixed sample size of 30 patients will be recruited over approximately 12 months, with survival follow-up extending to 36 months. This exploratory study is designed to generate preliminary efficacy and safety signals to inform future larger-scale investigations. The safety run-in design ensures close monitoring for potential additive toxicities, particularly given the novel combination of PCSK9 inhibition with immunotherapy and chemotherapy.

연구 개요

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310003
        • he First Affiliated Hospital, College of Medicine, Zhejiang University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Fully understood the study and voluntarily signed the Informed Consent Form (ICF);
  2. Aged 18-75 years, male or female;
  3. Histopathologically confirmed pMMR/MSS type gastric/gastroesophageal junction adenocarcinoma;
  4. Initially unresectable, advanced gastric/gastroesophageal junction adenocarcinoma;
  5. ECOG performance status 0-1;
  6. Life expectancy exceeding 3 months;
  7. Presence of measurable disease as confirmed by the investigator according to RECIST 1.1 criteria;
  8. Patients currently taking statin lipid-lowering medications must discontinue for ≥4 days before enrollment in this study;
  9. Adequate major organ function meeting the following requirements (laboratory values must meet the following criteria within 7 days before enrollment):

    • Hematology (no transfusion, no granulocyte colony-stimulating factor [G-CSF], no medication correction within 14 days before screening):
    • Neutrophils ≥ 1.5 × 10⁹/L;
    • Platelets ≥ 75 × 10⁹/L;
    • Hemoglobin ≥ 90 g/L;
    • Biochemistry (no albumin infusion within 14 days before screening):
    • Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance > 50 mL/min;
    • Serum total bilirubin ≤ 1.5 × ULN (subjects with Gilbert's syndrome are allowed total bilirubin ≤ 3 × ULN);
    • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN; for subjects with liver metastases, ALT and AST ≤ 5 × ULN;

    Coagulation function:

    - International Normalized Ratio (INR) ≤ 2.3 or Prothrombin Time (PT) exceeding normal control by ≤ 6 seconds;

  10. No severe concomitant diseases leading to a life expectancy < 5 years;
  11. Agree to provide blood and tissue samples for molecular biology testing;
  12. For patients with active Hepatitis B Virus (HBV) infection: HBV-DNA must be < 500 IU/mL (if the study center only uses copy/mL units, must be < 2500 copies/mL), and willing to receive antiviral therapy throughout the study period; Hepatitis C Virus (HCV) RNA-positive patients must receive antiviral therapy according to local standard treatment guidelines and have liver function elevations within CTCAE Grade 1;
  13. Within 28 days before enrollment, females of childbearing potential must have a confirmed negative serum pregnancy test and agree to use effective contraception during study drug administration and for 60 days after the last dose. For this protocol, females of childbearing potential are defined as sexually mature women who: 1) have not undergone hysterectomy or bilateral oophorectomy; 2) have not been naturally postmenopausal for at least 24 consecutive months (cancer treatment-induced amenorrhea does not rule out childbearing potential) (i.e., have had menstruation at any time in the preceding 24 consecutive months). Male subjects' female partners of childbearing potential should also follow the above contraceptive requirements.

Exclusion Criteria:

  1. HER2 positive (IHC 3+, or IHC 2+ with positive in situ hybridization);
  2. EBER positive;
  3. CLDN18.2 positive (≥ 75% of tumor cells with membranous staining of IHC intensity 2+/3+);
  4. Currently participating in other interventional clinical studies;
  5. Low-density lipoprotein cholesterol (LDL-C) controlled below 30 mg/dL (≈ 0.78 mmol/L);
  6. History of allergic reaction to PCSK9 inhibitors;
  7. Concurrent other active malignancy within the last 5 years besides gastric/gastroesophageal junction adenocarcinoma that has not recovered; Patients preparing for or having previously received organ or allogeneic bone marrow transplantation;
  8. Received major surgery (excluding diagnostic) within 4 weeks before start of study treatment or expected to require major surgery during the study (excluding radical gastrectomy);
  9. Currently have interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that might interfere with the judgment and management of immune-related pulmonary toxicity, or evidence of active pneumonitis on chest computed tomography (CT) scan during the screening period, or severely impaired pulmonary function.Subjects with radiation pneumonitis in the radiation field are allowed; active tuberculosis;

11. Presence of active autoimmune disease or a history of autoimmune disease that may recur (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism [subjects controlled by hormone replacement therapy alone can be included]); subjects with skin diseases not requiring systemic treatment such as vitiligo, psoriasis, alopecia, controlled Type I diabetes mellitus receiving insulin therapy, or childhood asthma that has completely resolved and requires no intervention in adulthood can be included; asthma patients requiring bronchodilators for medical intervention cannot be included; 12. History of uncontrolled epilepsy, central nervous system disease, or mental disorders, judged by the investigator as to whether clinical severity interferes with signing informed consent or affects patient compliance with medication; 13. Clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) Class II or more severe congestive heart failure, or severe arrhythmia requiring medical intervention, or history of myocardial infarction within the last 12 months; 14. Severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases; 15. Allergy or contraindication to the components of the study drugs (PCSK9 inhibitor, PD-1 monoclonal antibody, or chemotherapeutic agents); 16. Prior receipt of any anti-tumor therapy for gastric/gastroesophageal junction adenocarcinoma, including radiotherapy, chemotherapy, systemic therapy, etc.; 17. Use of immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose > 10 mg/day prednisone or equivalent) within 14 days before the start of study treatment; 18. Patients with congenital or acquired immunodeficiency (e.g., HIV infection); 19. Co-infection with Hepatitis B and Hepatitis C; 20. Prior receipt of other anti-PD-1 antibody therapy or other immunotherapy targeting PD-1/PD-L1, or prior receipt of PCSK9 monoclonal antibody therapy; 21. Receipt of live attenuated vaccine within 28 days before start of study treatment, or expected need for such vaccination during PD-1 monoclonal antibody treatment or within 60 days after the last dose of PD-1 monoclonal antibody; 22. Receipt of investigational drug (i.e., participating in another trial), anti-tumor cytotoxic drug therapy, biological drug therapy (e.g., monoclonal antibodies), immunotherapy (e.g., interleukin-2 or interferon) within 4 weeks before study enrollment; 23. Judged by the investigator, patients have other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, severe laboratory abnormalities, family or social factors, etc., that might affect subject safety or compliance; 24. Subjects with active tuberculosis (TB), receiving anti-tuberculosis treatment, or having received anti-tuberculosis treatment within 1 year before screening; 25. Pregnant or breastfeeding women.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment
Drug: S-1, oxaliplatin (SOX) Drug: Tafolecimab Drug: Sintilimab
Tafolecimab: 300 mg, subcutaneous injection, d1, Q3W Sintilimab 200 mg, intravenous infusion, d1, Q3W; SOX: S-1: 40 mg/m², oral, bid, d1-14, Oxaliplatin: 130 mg/m², 2-hour intravenous infusion, d1 Q3W

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate
기간: At the end of Cycle 2 (each cycle is 21 days)
Evaluate ORR and DCR (CR/PR/SD/PD) according to RECIST v1.1
At the end of Cycle 2 (each cycle is 21 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival
기간: 3-year
Defined as the time from randomization to the date of first disease progression (radiologic) or death from any cause, whichever occurs first. Subjects without disease progression or death are censored at the date of the last adequate tumor assessment.
3-year
Overall Survival
기간: 3-year
Defined as the time from randomization to the date of death from any cause. Subjects still alive at the end of the study are censored at the last known date alive
3-year
Conversion Surgery Rate
기간: From enrollment to the end of treatment at 24 weeks
Proportion of patients undergoing surgery among all treated patients
From enrollment to the end of treatment at 24 weeks
R0 Resection Rate
기간: From enrollment to the end of treatment at 24 weeks
Proportion of R0 resections among all patients undergoing surgery
From enrollment to the end of treatment at 24 weeks
Pathological Complete Response Rate
기간: From enrollment to the end of treatment at 24 weeks
Complete tumor regression in the primary tumor and lymph nodes upon postoperative pathology review
From enrollment to the end of treatment at 24 weeks
Major Pathological Response Rate
기간: From enrollment to the end of treatment at 24 weeks
Residual tumor cells ≤ 10% upon postoperative pathology review
From enrollment to the end of treatment at 24 weeks
Incidence of treatment-related adverse events
기간: through study completion, an average of 3 year
Incidence of Treatment-Related Adverse Events (TRAEs), common treatment-related adverse events, and incidence of Serious Adverse Events (SAEs) or ≥ Grade 3 treatment-related adverse events.
through study completion, an average of 3 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 5일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2030년 9월 1일

연구 등록 날짜

최초 제출

2026년 4월 21일

QC 기준을 충족하는 최초 제출

2026년 5월 27일

처음 게시됨 (실제)

2026년 6월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 27일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

위 선암종에 대한 임상 시험

구독하다